{"created":"2023-05-15T16:33:00.445768+00:00","id":5073,"links":{},"metadata":{"_buckets":{"deposit":"12b78c3b-50b7-41c4-9698-9e013afd8542"},"_deposit":{"created_by":2,"id":"5073","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"5073"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00005073","sets":["29:30"]},"author_link":["21013","21033","21018","21036","21030","21023","21025","21022","21034","21016","21014","21026","21015","21024","21027","21029","21035","21012","21017","21028","21020","21019","21031","21032","21021","21011"],"item_2_alternative_title_19":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Evaluation of pharmacokinetics and safety of liposomal amphotericin B (L-AMB) in patients with deep-seated fungal infection"}]},"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2013-07","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"379","bibliographicPageStart":"369","bibliographicVolumeNumber":"61","bibliographic_titles":[{"bibliographic_title":"日本化学療法学会雑誌"},{"bibliographic_title":"Japanese Journal of Chemotherapy","bibliographic_titleLang":"en"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"深在性真菌症罹患患者32名（23～73歳）を対象にLiposomal amphotericin B（L-AMB）を1.0 mg/kg/日，2.5 mg/kg/日または5.0 mg/kg/日の用量で原則7日間連日点滴静注し，薬物動態と安全性を検討した。L-AMB投与1日目の薬物動態ではCmax（平均値±標準偏差）は1.0 mg/kg/日，2.5 mg/kg/日，5.0 mg/kg/日の各用量でそれぞれ5.96±3.02 μg/mL，16.19±7.41 μg/mL，45.71±20.14 μg/mL，また，AUC0-24（平均値±標準偏差）では55.5±39.0 μg・hr/mL，138.5±56.5 μg・hr/mL，390.3±223.2 μg・hr/mLと用量が増すにつれ増加したが，投与量に対し非線形的な相関を示した。副作用は，用量が増すにつれ種類，頻度が増加する傾向にあった。1.0 mg/kg/日投与群で14例中10例（71.4％），2.5 mg/kg/日投与群で9例中8例（88.9％），5.0 mg/kg/日投与群で9例中9例（100％）であった。しかし，本剤の投与を制限する重篤な副作用は認められず，1.0 mg/kg/日～5.0 mg/kg/日を連日投与した場合の安全性と忍容性が確認された。","subitem_description_type":"Abstract"},{"subitem_description":"The pharmacokinetics and safety of liposomal amphotericin B (L-AMB) were evaluated in 32 patients with deep-seated fungal infections (age, 23-73 years) after intravenous infusion at a dose of 1.0, 2.5, or 5.0 mg/kg/day for seven consecutive days. On Day 1 of treatment with L-AMB at doses of 1.0, 2.5, and 5.0 mg/kg/day, the Cmax (mean ± standard deviation [SD]) was 5.96 ± 3.02, 16.19 ± 7.41, and 45.71 ± 20.14 μg/mL, respectively, and the AUC0-24 (mean ± SD) was 55.5 ± 39.0, 138.5 ± 56.5, and 390.3 ± 223.2 μg・hr/mL, respectively. The Cmax and AUC0-24 increased with increasing doses, but not in a linear manner. The type and incidence of adverse drug reactions tended to increase with increasing doses. Adverse drug reactions were reported in 10 (71.4%) of the 14 subjects in the 1.0-mg/kg/day group, 8 (88.9%) of the 9 subjects in the 2.5-mg/kg/day group, and all (100%) of the 9 subjects in the 5.0-mg/kg/day group. However, no serious, dose-limiting adverse drug reactions occurred, demonstrating the safety and tolerability of daily treatment with L-AMB at doses of 1.0 to 5.0 mg/kg/day.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"日本化学療法学会雑誌,  61(4), pp.369-379, 2013","subitem_description_type":"Other"}]},"item_2_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"21024","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Kohno, Shigeru"}]},{"nameIdentifiers":[{"nameIdentifier":"21025","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Kobayashi, Hiroyuki"}]},{"nameIdentifiers":[{"nameIdentifier":"21026","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Masaoka, Toru"}]},{"nameIdentifiers":[{"nameIdentifier":"21027","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Urabe, Akio"}]},{"nameIdentifiers":[{"nameIdentifier":"21028","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Kanamaru, Akihisa"}]},{"nameIdentifiers":[{"nameIdentifier":"21029","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Niki, Yoshihito"}]},{"nameIdentifiers":[{"nameIdentifier":"21030","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Mori, Takeshi"}]},{"nameIdentifiers":[{"nameIdentifier":"21031","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Hara, Kohei"}]},{"nameIdentifiers":[{"nameIdentifier":"21032","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Ikemoto, Hideo"}]},{"nameIdentifiers":[{"nameIdentifier":"21033","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Maniwa, Takashi"}]},{"nameIdentifiers":[{"nameIdentifier":"21034","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Nakajo, Eiji"}]},{"nameIdentifiers":[{"nameIdentifier":"21035","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Suzuki, Kota"}]},{"nameIdentifiers":[{"nameIdentifier":"21036","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Yamaguchi, Hideyo"}]}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本化学療法学会"}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"c 日本化学療法学会　All rights reserved."},{"subitem_rights":"利用は著作権の範囲内に限られる。"}]},"item_2_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN10472127","subitem_source_identifier_type":"NCID"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"13407007","subitem_source_identifier_type":"ISSN"}]},"item_2_text_62":{"attribute_name":"出版者別言語","attribute_value_mlt":[{"subitem_text_value":"Japan Society of Chemotherapy"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"河野, 茂"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"小林, 宏行"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"正岡, 徹"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"浦部, 晶夫"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"金丸, 昭久"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"二木, 芳人"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"森, 健"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"原, 耕平"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"池本, 秀雄"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"馬庭, 貴司"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"中條, 英司"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"鈴木, 孝太"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"山口, 英世"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-21"}],"displaytype":"detail","filename":"JJC61_369.pdf","filesize":[{"value":"688.5 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"JJC61_369.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/5073/files/JJC61_369.pdf"},"version_id":"d0394b9a-7368-4b9d-8b5f-9cae25869606"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Deep-seated fungal infection","subitem_subject_scheme":"Other"},{"subitem_subject":"Liposomal amphotericin B","subitem_subject_scheme":"Other"},{"subitem_subject":"Pharmacokinetics","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"深在性真菌症患者におけるLiposomal Amphotericin B（L-AMB）の薬物動態および安全性の検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"深在性真菌症患者におけるLiposomal Amphotericin B（L-AMB）の薬物動態および安全性の検討"}]},"item_type_id":"2","owner":"2","path":["30"],"pubdate":{"attribute_name":"公開日","attribute_value":"2014-02-07"},"publish_date":"2014-02-07","publish_status":"0","recid":"5073","relation_version_is_last":true,"title":["深在性真菌症患者におけるLiposomal Amphotericin B（L-AMB）の薬物動態および安全性の検討"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T03:12:02.881102+00:00"}